Hutchison Pharmaceutical announced today that following the announcement of September 3, 2026, and completion of customary transaction conditions, including antitrust reviews, the exclusive development and licensing agreement between the Company's subsidiary Hutchison Whampoa Pharmaceuticals Limited and a subsidiary of GSK plc has been completed. The agreement grants the GlaxoSmithKline subsidiary the right to develop and commercialize HMPL-A830 globally outside of mainland China, Hong Kong, Macau, and Taiwan. According to the terms of the agreement, Hutchison Whampoa Pharmaceutical Co., Ltd. will be responsible for the global Phase I development project for HMPL-A830. GlaxoSmithKline subsidiaries will be responsible for all subsequent clinical development and commercialization within their authorized regions. After the settlement of this exclusive license agreement is completed, Hutchison Whampoa Pharmaceutical Co., Ltd. is expected to receive a down payment of US$110 million in the short term, and can also collect up to US$1,185 million in regulatory, development and commercial sales milestone payments, and also receive tiered royalties based on net sales.

Zhitongcaijing · 2d ago
Hutchison Pharmaceutical announced today that following the announcement of September 3, 2026, and completion of customary transaction conditions, including antitrust reviews, the exclusive development and licensing agreement between the Company's subsidiary Hutchison Whampoa Pharmaceuticals Limited and a subsidiary of GSK plc has been completed. The agreement grants the GlaxoSmithKline subsidiary the right to develop and commercialize HMPL-A830 globally outside of mainland China, Hong Kong, Macau, and Taiwan. According to the terms of the agreement, Hutchison Whampoa Pharmaceutical Co., Ltd. will be responsible for the global Phase I development project for HMPL-A830. GlaxoSmithKline subsidiaries will be responsible for all subsequent clinical development and commercialization within their authorized regions. After the settlement of this exclusive license agreement is completed, Hutchison Whampoa Pharmaceutical Co., Ltd. is expected to receive a down payment of US$110 million in the short term, and can also collect up to US$1,185 million in regulatory, development and commercial sales milestone payments, and also receive tiered royalties based on net sales.